Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: two randomized …

JY Kim, YR Jang, JH Hong, JG Jung, JH Park… - Clinical Therapeutics, 2021 - Elsevier
Purpose Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and
pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal …
被引用次数：54 相关文章
[HTML] nih.gov

[HTML][HTML] Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two …

JY Kim, YR Jang, JH Hong, JG Jung, JH Park… - Clinical …, 2021 - ncbi.nlm.nih.gov
Purpose Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and
pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal …

Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two …

JY Kim, YR Jang, JH Hong, JG Jung, JH Park… - 2021 - pubmed.ncbi.nlm.nih.gov
Purpose Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and
pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal …

Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: two randomized …

JY Kim, RY Jang, JH Hong, JG Jung, JH Park… - 2021 - cabidigitallibrary.org
Purpose: Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and
pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal …

Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two …

JY Kim, YR Jang, JH Hong, JG Jung, JH Park… - Clinical …, 2021 - europepmc.org
Purpose Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and
pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal …

Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two …

JY Kim, YR Jang, JH Hong, JG Jung… - Clinical …, 2021 - clinicaltherapeutics.com
Purpose Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and
pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal …

Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two …

JY Kim, YR Jang, JH Hong, JG Jung, JH Park… - Clinical …, 2021 - europepmc.org
Purpose Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and
pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal …